News

Fintel reports that on August 3, 2023, HC Wainwright & Co. reiterated coverage of Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy recommendation.

Analyst Price Forecast Suggests 44.43% Upside

As of August 2, 2023, the average one-year price target for Intercept Pharmaceuticals is 15.56. The forecasts range from a low of 10.10 to a high of $21.00. The average price target represents an increase of 44.43% from its latest reported closing price of 10.77.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for Intercept Pharmaceuticals is 333MM, an increase of 8.65%. The projected annual non-GAAP EPS is -2.70.

What is the Fund Sentiment?

There are 319 funds or institutions reporting positions in Intercept Pharmaceuticals. This is a decrease of 10 owner(s) or 3.04% in the last quarter. Average portfolio weight of all funds dedicated to ICPT is 0.05%, a decrease of 28.74%. Total shares owned by institutions decreased in the last three months by 1.40% to 32,044K shares.

The put/call ratio of ICPT is 1.49, indicating a bearish outlook.

What are Other Shareholders Doing?

XBI - SPDR(R) S&P(R) Biotech ETF holds 2,416K shares representing 5.79% ownership of the company. In it's prior filing, the firm reported owning 2,567K shares, representing a decrease of 6.29%. The firm increased its portfolio allocation in ICPT by 27.60% over the last quarter.

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,123K shares representing 2.69% ownership of the company. No change in the last quarter.

VSEQX - Vanguard Strategic Equity Fund Investor Shares holds 1,078K shares representing 2.59% ownership of the company. In it's prior filing, the firm reported owning 934K shares, representing an increase of 13.38%. The firm increased its portfolio allocation in ICPT by 22.30% over the last quarter.

Renaissance Technologies holds 1,050K shares representing 2.52% ownership of the company. In it's prior filing, the firm reported owning 708K shares, representing an increase of 32.56%. The firm increased its portfolio allocation in ICPT by 56.13% over the last quarter.

Jacobs Levy Equity Management holds 923K shares representing 2.22% ownership of the company. In it's prior filing, the firm reported owning 923K shares, representing an increase of 0.03%. The firm decreased its portfolio allocation in ICPT by 1.63% over the last quarter.

Intercept Pharmaceuticals Background Information
(This description is provided by the company.)

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.

Additional reading:

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.